You are here

Mitigating ARS in the Mouse Gut

Exposure to lethal doses of ionizing radiation manifests as acute radiation syndrome (ARS), with the extent of radiation damage to the hematopoietic and gastrointestinal (GI) systems codetermining the acute survival of the exposed individual. In a recent STEM CELLS Translational Medicine article, researchers led by Frank Pajonk (UCLA, Los Angeles, California, USA) report that a piperazine compound prevents ARS in the mouse gut when given 24 hours after a lethal dose of radiation. Moreover, Duhachek‐Muggy et al. also uncover the underlying mechanism of action, thus providing a basis for the future rational development of effective radiation mitigators.